Adaptive Biotechnologies Aktie - ADPT

Rendering Error

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

8,4099

Gebot

7,77

Fragen

8,47

Volumen

2.597.520

7,80 Tagesbereich 8,66

2,28 52-Wochen-Bereich 8,94

Marktkapitalisierung

1,25B

Handelsende

7,75

Handelsbeginn

7,895

Letzte Trade

8.41

Letzter Handelszeitpunkt

Finanzvolumen

US$ 21.327.423

VWAP

8,2107

Durchschnittliches Volumen (3 Mio.)

1.629.520

Ausgegebene Aktien

148.582.201

Dividendenrendite

Kurs-Gewinn-Verhältnis

-7,83

Gewinn pro Aktie (EPS)

-1,07

Erlöse

178,96M

Nettogewinn

-159,49M

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for... Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Mehr anzeigen

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.adaptivebiotech.com

Hauptsitz

Olympia, Washington, USA

Gegründet

Adaptive Biotechnologies Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ADPT. The last closing price for Adaptive Biotechnologies was US$7,75. Over the last year, Adaptive Biotechnologies shares have traded in a share price range of US$ 2,28 to US$ 8,94.

Adaptive Biotechnologies currently has 148.582.201 shares in issue. The market capitalisation of Adaptive Biotechnologies is US$1,15 billion. Adaptive Biotechnologies has a price to earnings ratio (PE ratio) of -7.83.

Form 4 - Statement of changes in beneficial ownership of securities

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	1.1099	15.204109589	7.3	8.4099	6.915	1902562	7.48877651	CS
4	-0.0601	-0.709563164109	8.47	8.94	6.255	1843814	7.71015451	CS
12	1.9399	29.9829984544	6.47	8.94	5.91	1629520	7.59551791	CS
26	3.6999	78.5541401274	4.71	8.94	3.981	1394407	6.56548314	CS
52	4.9999	146.624633431	3.41	8.94	2.28	1437407	4.99615001	CS
156	-4.3901	-34.29765625	12.8	15.19	2.28	1322059	6.37550024	CS
260	-14.7601	-63.7034958999	23.17	71.25	2.28	1153290	16.24969629	CS

ADPT - Frequently Asked Questions (FAQ)

What is the current Adaptive Biotechnologies share price?

The current share price of Adaptive Biotechnologies is US$ 8,4099

How many Adaptive Biotechnologies shares are in issue?

Adaptive Biotechnologies has 148.582.201 shares in issue

What is the market cap of Adaptive Biotechnologies?

The market capitalisation of Adaptive Biotechnologies is USD 1,15B

What is the 1 year trading range for Adaptive Biotechnologies share price?

Adaptive Biotechnologies has traded in the range of US$ 2,28 to US$ 8,94 during the past year

What is the PE ratio of Adaptive Biotechnologies?

The price to earnings ratio of Adaptive Biotechnologies is -7,83

What is the cash to sales ratio of Adaptive Biotechnologies?

The cash to sales ratio of Adaptive Biotechnologies is 6,97

What is the reporting currency for Adaptive Biotechnologies?

Adaptive Biotechnologies reports financial results in USD

What is the latest annual turnover for Adaptive Biotechnologies?

The latest annual turnover of Adaptive Biotechnologies is USD 178,96M

What is the latest annual profit for Adaptive Biotechnologies?

The latest annual profit of Adaptive Biotechnologies is USD -159,49M

What is the registered address of Adaptive Biotechnologies?

The registered address for Adaptive Biotechnologies is 711 CAPITOL WAY S STE 204, UNITED STATES, OLYMPIA, WASHINGTON, 98501 1267

What is the Adaptive Biotechnologies website address?

The website address for Adaptive Biotechnologies is www.adaptivebiotech.com

Which industry sector does Adaptive Biotechnologies operate in?

Adaptive Biotechnologies operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SGLYSingularity Future Technology Ltd	US$ 1,6799 (143,43%)	30,75M
WINVWinVest Acquisition Corporation	US$ 25,00 (107,30%)	463
VVPRVivoPower International PLC	US$ 1,2899 (52,13%)	65,08M
RNAZTransCode Therapeutics Inc	US$ 1,12 (45,45%)	216,2M
GLTOGalecto Inc	US$ 6,00 (44,93%)	10,71M
YHCLQR House Inc	US$ 0,40 (-82,38%)	38,28M
KZIAKazia Therapeutics Ltd	US$ 0,9759 (-80,02%)	55,66k
DMNDamon Inc	US$ 0,0373 (-70,02%)	304,07M
TCBPTC BioPharm Holdings PLC	US$ 0,5046 (-67,23%)	5,89M
SOWGSow Good Inc	US$ 1,53 (-44,36%)	697,78k
DMNDamon Inc	US$ 0,0373 (-70,02%)	304,07M
NVDANVIDIA Corporation	US$ 117,70 (-0,70%)	264,41M
RNAZTransCode Therapeutics Inc	US$ 1,12 (45,45%)	216,2M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 9,03 (10,66%)	175,73M
HOLOMicroCloud Hologram Inc	US$ 1,00 (32,36%)	141,95M

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Adaptive Biotechnologies Corporation (ADPT) Börsenkurse

Adaptive Biotechnologies Corporation (ADPT)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Adaptive Biotechnologies Corporation

ADPT Neueste Nachrichten

Form 4 - Statement of changes in beneficial ownership of securities

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ADPT - Frequently Asked Questions (FAQ)

Beweger

ADPT Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen